(1) succesfuld behandling af enhver baseline svampeinfektion (caspofungin 51, 9% [14/ 27], liposomal amphotericin B 25, 9% [7/ 27]), (2) ingen ny - eller genopstået svampeinfektion under administration af studiemedicinen og i op til 7 dage efter endt behandling (caspofungin 94, 8% [527/ 556], liposomal amphotericin B 95, 5% [515/ 539]), (3) overlevelse i 7 dage efter afsluttet behandling med studiemedicin (caspofungin 92, 6% [515/ 556], liposomal amphotericin B 89, 2% [481/ 539]), (4) ingen afbrydelse af behandling med studiemedicinen på grund af lægemiddelrelateret toksicitet eller manglende effekt caspofungin 89, 7% [499/ 556], liposomal amphotericin B 85, 5% [461/ 539]), og (5) resolution af feber i perioden med neutropeni (caspofungin 41, 2% [229/ 556], liposomal amphotericin B 41, 4% [223/ 539]).
(1) successful treatment of any baseline fungal infection (caspofungin 51.9% [14/ 27], liposomal amphotericin B 25.9% [7/ 27]), (2) no breakthrough fungal infections during administration of study drug or within 7 days after completion of treatment (caspofungin 94.8% [527/ 556], liposomal amphotericin B 95.5% [515/ 539]), (3) survival for 7 days after completion of study therapy (caspofungin 92.6% [515/ 556], liposomal amphotericin B 89.2% [481/ 539]), (4) no discontinuation from the study drug because of drug-related toxicity or lack of efficacy (caspofungin 89.7% [499/ 556], liposomal amphotericin B 85.5% [461/ 539]), and (5) resolution of fever during the period of neutropaenia (caspofungin 41.2% [229/ 556], liposomal amphotericin B 41.4% [223/ 539]).